This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): KCA-757, MN-002 (Metabolite)
Description: MN-001 is an oral agent that reportedly has attributes of leukotriene antagonists and inhaled steroids. In addition to leukotriene receptor antagonism, it inhibits phosphodiesterases III and IV, 5-lipoxygenase, phospholipase C and thromboxane A2. Preclinical studies have demonstrated that MN-001 inhibits the airway hyper-reactivity that causes bronchoconstriction through a reduction of airway inflammation.
Deal Structure: On March 14, 2002, MediciNova entered into an exclusive license agreement with Kyorin Pharmaceutical for the development and commercialization of MN-001. MediciNova obtained an exclusive, worldwide (excluding Japan, China, South Korea, and Taiwan) sublicenseable license to the patent rights and know-how related to MN-001 and its active metabolite, MN-002, disclosed and included in, or covered by, these patents, in all indications except for ophthalmic solution formulations. The U.S. composition of matter patents for MN-001 and MN-002 underlying the license are set to expire on February 23, 2009 and December 30, 2011, respectively. Corresponding composition of matter patents in various other countries are set to expire no earlier than between March 1, 2009 and January 15, 2015. Notices of allowance for two patent applications covering certain compositions, uses and methods of manufacturing of MN-001 was received recently, extending exclusivity through 2023.
Partners: Kyorin Pharmaceutical Co., Ltd.
Additional information available to subscribers only: